Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease (AD)

Viewpoint discusses the potential US FDA approval of aducanumab, a monoclonal antibody, for the treatment of AD dementia; including the long-awaited advent of disease-modifying therapy for AD, as well as the significant challenges for AD clinical practice and research.

Source:

JAMA Neurology